GO:0051057 positive regulation of small GTPase mediated signal transduction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051057 describes any process that activates or increases the frequency, rate or extent of small GTPase mediated signal transduction.
• Small GTPases such as KRAS, RAP1, RAC1, CDC42, and RHO act as molecular switches that cycle between inactive GDP-bound and active GTP-bound states.
• Positive regulation is achieved by guanine nucleotide exchange factors (GEFs), GTPase-activating protein (GAP) inhibition, and post-translational modifications that enhance GTP loading.
• Dysregulated positive regulation of small GTPase signaling drives cancer, developmental disorders, immune dysfunction, and neurological disease [1,2,4,7].
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of GTPase regulators in disease [2,4,7].
• Key experimental approaches include Ribo-seq, RNA-seq, proteomics, live-cell imaging, and CRISPR library screening.
Description
Small GTPases are a superfamily of hydrolase enzymes that function as binary molecular switches, cycling between an inactive GDP-bound state and an active GTP-bound state to control diverse cellular processes including proliferation, differentiation, cytoskeletal dynamics, and vesicle trafficking. The Gene Ontology term GO:0051057, positive regulation of small GTPase mediated signal transduction, captures any process that activates or increases the frequency, rate or extent of signal transduction mediated by these switches. This term is critical for researchers because the intensity and duration of small GTPase signaling must be tightly controlled; excessive or inappropriate activation underlies many human diseases, particularly cancer and developmental syndromes [1,2,7]. Mechanistically, positive regulation of small GTPase signaling is primarily executed by guanine nucleotide exchange factors (GEFs) that catalyze the exchange of GDP for GTP, by GAP inhibitors that prevent GTP hydrolysis, and by post-translational modifications that alter GTPase localization or activity. For example, dominant mutations in LZTR1 that impair its Kelch domain substrate-recognition surface lead to enhanced RAS-MAPK signaling, demonstrating how loss of negative regulation can result in positive pathway output. Similarly, the RASH3D19 isoform mediates RAS activation through a positive feedback loop in KRAS-mutant cancer, illustrating the complexity of regulatory circuits that sustain oncogenic signaling. Understanding GO:0051057 is therefore essential for both basic cell biology and translational research. It provides a framework for interpreting how genetic lesions, epigenetic changes, and pharmacological interventions alter the signaling threshold of small GTPases. This article synthesizes authoritative QuickGO data and verified PubMed literature to describe the definition, mechanisms, key genes, disease links, and research methods relevant to this term.
positive regulation of small GTPase mediated signal transduction At A Glance
| GO ID | GO:0051057 |
|---|---|
| GO term | positive regulation of small GTPase mediated signal transduction |
| Ontology | biological_process |
| Synonym | activation of small GTPase mediated signal transduction; stimulation of small GTPase mediated signal transduction; up regulation of small GTPase mediated signal transduction |
| Major function | Enhances the frequency, rate or extent of signal transduction mediated by small GTPases, typically by promoting GTP loading or stabilizing active GTP-bound states. |
| Related negative regulation | GO:0051058 negative regulation of small GTPase mediated signal transduction |
| Core signal transduction term | GO:0007264 small GTPase mediated signal transduction |
| Example regulators | Guanine nucleotide exchange factors (GEFs), GAP inhibitors, post-translational modifiers |
| Disease relevance | Cancer, Noonan syndrome, immune evasion, neurological disorders [1,2,4,7] |
What Is GO:0051057?
GO:0051057, positive regulation of small GTPase mediated signal transduction, is defined by QuickGO as any process that activates or increases the frequency, rate or extent of small GTPase mediated signal transduction. In other words, it encompasses all molecular events that enhance the signaling output of small GTPases, such as promoting GTP loading, stabilizing the active conformation, or facilitating downstream effector engagement. This term is a biological process and is distinct from negative regulation (GO:0051058) and from the core signal transduction term itself (GO:0007264).
Why Is positive regulation of small GTPase mediated signal transduction Important in Cell Biology?
GO:0051057 is important because small GTPases control some of the most fundamental cellular decisions, and their hyperactivation is a common driver of human disease. For instance, KRAS-driven cancers often depend on sustained RAS activation, and glycosphingolipid synthesis has been shown to mediate immune evasion in such tumors. Dominant mutations in LZTR1 that enhance RAS-MAPK signaling cause Noonan syndrome, a developmental disorder. In the nervous system, activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization, highlighting the role of positive regulation in synaptic plasticity. Thus, understanding this term is essential for identifying therapeutic targets and designing experiments that manipulate GTPase signaling with precision.
• Cancer: Hyperactivation of RAS, RAC1, and RHO GTPases promotes proliferation, survival, and metastasis [1,7].
• Developmental disorders: Enhanced RAS-MAPK signaling due to LZTR1 mutations causes Noonan syndrome.
• Immune evasion: Glycosphingolipid synthesis sustains KRAS-driven immune evasion, linking positive regulation to tumor immunology.
• Neurological function: Cdc42 activation by Ephexin5 regulates synapse growth and stabilization.
• Inflammatory diseases: Ginseng exosomal miRNA ameliorates rheumatoid arthritis by mediating KRAS-MAPK signaling.
• Bone homeostasis: MiR-1224-5p modulates osteogenesis via the Rap1 signaling target ADCY2.
• Viral pathogenesis: Enterovirus 3A protein disrupts ER homeostasis through interaction with GBF1, affecting small GTPase-dependent trafficking.
• Therapeutic targeting: GEFs and GAPs are attractive drug targets for modulating GTPase signaling [2,7].
• Research tool development: CRISPR screens and genetically encoded biosensors enable precise manipulation and measurement of GTPase activity [4,7].
What Happens During positive regulation of small GTPase mediated signal transduction?
Guanine nucleotide exchange and GTP loading
In simple terms: GEFs help small GTPases swap GDP for GTP, turning them on.
The central step in positive regulation is the acceleration of GDP-to-GTP exchange, catalyzed by guanine nucleotide exchange factors (GEFs). GEFs bind to the GDP-bound GTPase, destabilize the nucleotide-binding pocket, and promote the release of GDP, allowing the more abundant GTP to bind. This converts the GTPase to its active, GTP-bound conformation, which can then engage downstream effectors. For example, RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer, illustrating how exchange activity can be amplified.
Inhibition of GTP hydrolysis
In simple terms: Blocking the off-switch keeps GTPases active longer.
GTPase-activating proteins (GAPs) accelerate the intrinsic hydrolysis of GTP to GDP, terminating signaling. Positive regulation can occur when GAP activity is inhibited or when GAPs are prevented from accessing the GTPase. Dominant mutations in LZTR1 that affect its Kelch domain substrate-recognition surface lead to enhanced RAS-MAPK signaling, likely by impairing its ability to promote GTP hydrolysis or by disrupting a GAP complex. Thus, inhibition of the off-switch is a key mechanism for sustaining active GTPase signaling.
Post-translational modifications and localization
In simple terms: Chemical tags and location changes can turn GTPases on.
Post-translational modifications such as phosphorylation, prenylation, and ubiquitination can alter the localization, stability, or interaction profile of small GTPases and their regulators. For instance, glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer, suggesting that lipid metabolism can influence the membrane environment where RAS signals. Similarly, activity-dependent regulation of Cdc42 by Ephexin5 involves dynamic changes in localization that drive synapse growth and stabilization. These modifications often act in concert with GEFs and GAPs to fine-tune signaling output.
Effector engagement and downstream amplification
In simple terms: Active GTPases bind effectors that relay the signal.
Once in the GTP-bound state, small GTPases interact with downstream effectors such as RAF kinases, PI3K, and WASP family proteins, propagating the signal. Positive regulation can also occur at this level if effector binding is enhanced or if scaffolding proteins increase the efficiency of signal transmission. For example, MiR-1224-5p modulates osteogenesis by coordinating osteoblast/osteoclast differentiation via the Rap1 signaling target ADCY2, demonstrating how a GTPase pathway can be amplified through downstream targets. In rheumatoid arthritis, ginseng exosomal miRNA ameliorates inflammation by mediating KRAS-MAPK signaling, further highlighting effector-level control.
Feedback loops and crosstalk
In simple terms: Signals can loop back to keep GTPases active.
Positive regulation often involves feedback loops where downstream effectors or parallel pathways enhance upstream GTPase activation. RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer, meaning that active RAS promotes further RAS activation. Such loops can create bistable switches and contribute to oncogenic addiction. Crosstalk with other signaling cascades, such as the MAPK pathway, can also reinforce GTPase activation, as seen in Noonan syndrome where LZTR1 mutations enhance RAS-MAPK signaling.
Key Genes Involved in GO:0051057 positive regulation of small GTPase mediated signal transduction
The following genes and proteins are central to positive regulation of small GTPase mediated signal transduction, based on verified literature and their established roles in GTPase cycling, effector engagement, and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KRAS | Small GTPase; cycles between GDP/GTP states to control proliferation | Mutations drive many cancers; target of immune evasion studies [1,7] |
| LZTR1 | Substrate-recognition component of a CRL3 ubiquitin ligase complex; regulates RAS-MAPK signaling | Mutations cause Noonan syndrome and enhance RAS signaling |
| RAP1 | Small GTPase regulating cell adhesion, junction formation, and differentiation | Modulates osteogenesis via ADCY2 |
| CDC42 | Small GTPase controlling actin cytoskeleton and synapse growth | Regulated by Ephexin5 in activity-dependent synapse stabilization |
| RAC1 | Small GTPase involved in cytoskeletal reorganization and NADPH oxidase activation | Implicated in cancer and immune cell function |
| RHOA | Small GTPase regulating actomyosin contractility and cell migration | Frequently dysregulated in cancer and developmental disorders |
| GBF1 | GEF for ARF GTPases; regulates ER-Golgi trafficking | Targeted by enterovirus 3A protein to disrupt ER homeostasis |
| ADCY2 | Adenylyl cyclase; downstream target of Rap1 signaling | Modulates osteoblast/osteoclast differentiation |
| EPHEXIN5 (ARHGEF15) | Rho GEF; activates Cdc42 | Activity-dependent regulation drives synapse growth |
| SOS1 | RAS GEF; activates KRAS | Proto-oncogene; mutations affect RAS signaling |
| NF1 | RAS GAP; inactivates KRAS | Tumor suppressor; loss enhances RAS signaling |
| PTPN11 | Protein tyrosine phosphatase; regulates RAS-MAPK signaling | Mutations cause Noonan syndrome and leukemia |
| RASA1 | RAS GAP; negative regulator of RAS | Mutations linked to vascular anomalies |
| ARHGEF2 | Rho GEF; activates RhoA and Rac1 | Involved in cytoskeletal dynamics and cancer |
| DOCK180 | GEF for Rac1; regulates cell migration | Role in cancer invasion and metastasis |
| TIAM1 | GEF for Rac1; regulates polarity and adhesion | Implicated in tumor progression |
| VAV1 | GEF for Rac1 and RhoA; immune cell signaling | Target in autoimmune and inflammatory diseases |
How Is positive regulation of small GTPase mediated signal transduction Regulated?
Positive regulation of small GTPase mediated signal transduction is itself tightly regulated at multiple levels. Upstream signals from receptor tyrosine kinases, G-protein coupled receptors, and integrins converge on GEFs and GAPs to modulate GTPase activity. For example, activity-dependent regulation of Cdc42 by Ephexin5 demonstrates how neuronal activity can locally control GEF function to drive synapse growth. In cancer, glycosphingolipid synthesis mediates immune evasion in KRAS-driven tumors, indicating that metabolic pathways can influence the membrane environment and sustain RAS activation. Additionally, microRNAs such as MiR-1224-5p can modulate Rap1 signaling by targeting downstream components like ADCY2, providing another layer of post-transcriptional control. Viral proteins, such as enterovirus 3A, can disrupt ER homeostasis by interacting with GBF1, thereby altering ARF GTPase regulation. These examples illustrate that positive regulation is context-dependent and subject to crosstalk with metabolic, immune, and developmental signaling networks.
positive regulation of small GTPase mediated signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer (pancreatic, lung, colorectal); immune evasion | KRAS G12D knock-in mouse; CRISPR KO in cancer cell lines [1,7] |
| LZTR1 | Noonan syndrome; enhanced RAS-MAPK signaling | LZTR1 point-mutation knock-in mice; patient-derived iPSCs |
| CDC42 | Synaptic dysfunction; neurodevelopmental disorders | Cdc42 KO neurons; Ephexin5 knockout mice |
| RAP1 | Osteogenesis; bone homeostasis | Rap1 KO osteoblast/osteoclast co-cultures; ADCY2 reporter |
| GBF1 | Viral pathogenesis; ER homeostasis | GBF1 KO cells; enterovirus 3A expression |
Cancer
Hyperactivation of small GTPases, particularly RAS family members, is a hallmark of many cancers. KRAS mutations are common in pancreatic, lung, and colorectal cancers, and sustained RAS signaling promotes proliferation, survival, and immune evasion. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer, linking positive regulation of GTPase signaling to tumor immunology. The RASH3D19 isoform mediates RAS activation through a positive feedback loop, further amplifying oncogenic signaling. Targeting positive regulators of GTPase signaling, such as GEFs, is therefore a promising therapeutic strategy.
Developmental disorders
Noonan syndrome is a developmental disorder caused by mutations in genes encoding components of the RAS-MAPK pathway. Dominant mutations in LZTR1 that affect its Kelch domain substrate-recognition surface enhance RAS-MAPK signaling, leading to craniofacial dysmorphism, cardiac defects, and short stature. This exemplifies how increased positive regulation of small GTPase signaling can cause developmental pathology.
Neurological and synaptic disorders
Small GTPases such as Cdc42 are critical for neuronal morphogenesis and synaptic plasticity. Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization, and dysregulation of this process may contribute to neurodevelopmental disorders. Understanding positive regulation in neurons could inform therapies for conditions involving synaptic dysfunction.
Inflammatory and immune diseases
Small GTPases regulate immune cell activation, migration, and cytokine production. Ginseng exosomal miRNA ameliorates rheumatoid arthritis by mediating KRAS-MAPK signaling, suggesting that modulating GTPase pathways can reduce inflammation. NK cell receptors also signal through small GTPases to control cytotoxicity, highlighting the importance of positive regulation in immune responses.
From positive regulation of small GTPase mediated signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a GEF reduce GTPase activation and downstream signaling? | CRISPR knockout of the GEF in cell lines, followed by GTPase activity assays |
| Does a specific point mutation in a GTPase regulator enhance signaling? | Point-mutation knock-in via CRISPR in isogenic cell lines or mice |
| Can a disease-associated mutation be corrected? | Knock-in of wild-type allele or base editing to revert mutation |
| Where and when is a GTPase activated in live cells? | Tagged knock-in of a GTPase biosensor (e.g., GFP-RBD) for live imaging |
| What is the effect of GTPase overexpression on phenotype? | Overexpression of wild-type or mutant GTPase using lentiviral vectors |
| Which genes modulate sensitivity to GTPase pathway inhibitors? | Genome-wide CRISPR library screening with drug selection |
How to Study the positive regulation of small GTPase mediated signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Genome-wide translation efficiency | Identify translationally regulated genes downstream of GTPase signaling |
| RNA-seq | Transcript abundance | Profile gene expression changes upon GTPase pathway manipulation |
| Proteomics | Protein abundance and modifications | Map signaling networks altered by LZTR1 mutations |
| Phosphoproteomics | Phosphorylation sites and kinetics | Identify effector kinase substrates in RAS-driven cancer |
| Live-cell imaging with biosensors | Real-time GTPase activity and localization | Study activity-dependent Cdc42 regulation at synapses |
| CRISPR library screening | Gene essentiality or drug sensitivity | Discover modifiers of KRAS immune evasion |
| GTPase activity assay (GST-RBD pulldown) | Levels of active GTP-bound GTPase | Validate GEF or GAP effects in knockout cells |
| Co-immunoprecipitation | Protein-protein interactions | Identify GEF-GTPase complexes |
Ribo-seq and RNA-seq
Ribo-seq measures genome-wide translation efficiency, while RNA-seq quantifies transcript abundance. These methods can reveal how positive regulators of small GTPase signaling affect the translatome and transcriptome. For example, in KRAS-driven cancer, glycosphingolipid synthesis mediates immune evasion, and RNA-seq could identify immune-related genes whose expression depends on RAS activation. Similarly, Ribo-seq can uncover translationally regulated targets downstream of Rap1 signaling in osteogenesis.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation status following manipulation of GTPase regulators. This is particularly useful for mapping signaling networks downstream of LZTR1 mutations in Noonan syndrome, where RAS-MAPK signaling is enhanced. Phosphoproteomics can identify effector kinases and feedback loops, such as those involving RASH3D19 in KRAS-mutant cancer.
Live-cell imaging and biosensors
Genetically encoded biosensors that report GTPase activity (e.g., Raichu probes) enable real-time visualization of GTP loading in living cells. Activity-dependent regulation of Cdc42 by Ephexin5 was dissected using such imaging approaches, revealing dynamic changes at synapses. Live imaging can also track the localization of GEFs and GAPs in response to stimuli.
CRISPR screens and functional genomics
Pooled CRISPR knockout or activation screens can identify genes that positively regulate small GTPase signaling. For instance, screens in KRAS-mutant cancer cells can uncover synthetic lethal interactions or modifiers of immune evasion. Such screens are powerful for discovering novel GEFs, GAPs, and downstream effectors.
How CRISPR Can Be Used to Study GO:0051057 positive regulation of small GTPase mediated signal transduction
Knockout
CRISPR knockout is used to delete genes encoding GEFs, GAPs, or GTPases themselves to determine their necessity for positive regulation. For example, knocking out LZTR1 in cell models can reveal its role in suppressing RAS-MAPK signaling, as mutations in its Kelch domain enhance signaling. Knockout of Ephexin5 can test its requirement for activity-dependent Cdc42 activation and synapse growth.
Point Mutation
CRISPR point-mutation knock-in introduces specific disease-associated mutations to study their effects on GTPase regulation. For instance, introducing Noonan syndrome-causing LZTR1 mutations into isogenic cell lines allows precise assessment of their impact on RAS-MAPK signaling. Similarly, point mutations in KRAS can be modeled to study isoform-specific activation mechanisms.
Knock-in
Knock-in of reporter tags or biosensors enables visualization and quantification of GTPase activity in live cells. Tagged knock-in of Cdc42 or its regulators can reveal spatiotemporal dynamics during synapse formation. Knock-in of wild-type alleles can also rescue phenotypes caused by knockout, confirming specificity.
Overexpression
Overexpression of wild-type or constitutively active GTPases or GEFs is used to drive pathway activation and assess downstream effects. For example, overexpression of RASH3D19 in KRAS-mutant cancer cells can amplify RAS activation through a positive feedback loop. Overexpression of Rap1 or its targets can modulate osteogenesis in vitro.
How EDITGENE Supports positive regulation of small GTPase mediated signal transduction Research
Researchers studying positive regulation of small GTPase mediated signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway activation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of GTPase regulators.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of small GTPase mediated signal transduction research.
Frequently Asked Questions About positive regulation of small GTPase mediated signal transduction
What is GO:0051057?
GO:0051057 is the Gene Ontology term for positive regulation of small GTPase mediated signal transduction, defined as any process that activates or increases the frequency, rate or extent of signal transduction mediated by small GTPases.
What genes are involved in positive regulation of small GTPase mediated signal transduction?
Key genes include KRAS, LZTR1, RAP1, CDC42, RAC1, RHOA, GBF1, and their regulators such as GEFs (SOS1, EPHEXIN5) and GAPs (NF1, RASA1) [1,2,4,5,7,8].
How does positive regulation of small GTPase signaling occur?
It occurs primarily through GEF-mediated GTP loading, inhibition of GAP activity, post-translational modifications, and feedback loops that sustain active GTP-bound states [2,7].
Why is positive regulation of small GTPase signaling important in cancer?
Hyperactivation of small GTPases like KRAS drives proliferation, survival, and immune evasion in many cancers, making this process a key therapeutic target [1,7].
What diseases are linked to dysregulated small GTPase signaling?
Diseases include cancer, Noonan syndrome, neurodevelopmental disorders, inflammatory diseases like rheumatoid arthritis, and viral pathogenesis [1,2,3,4,8].
How can CRISPR be used to study positive regulation of small GTPase signaling?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow precise manipulation of GTPase regulators to assess their causal roles in signaling and disease [2,4,7].
What methods are used to measure small GTPase activity?
Common methods include GST-RBD pulldown for active GTPase, live-cell imaging with biosensors, phosphoproteomics, and CRISPR screens [1,4,7].
What is the role of LZTR1 in small GTPase signaling?
LZTR1 is a substrate-recognition component that regulates RAS-MAPK signaling; dominant mutations enhance signaling and cause Noonan syndrome.
How does Cdc42 contribute to synapse growth?
Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization, highlighting its role in neuronal plasticity.
What CRISPR services does EDITGENE offer for GTPase research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics analysis tailored to small GTPase signaling studies.
Conclusion
GO:0051057, positive regulation of small GTPase mediated signal transduction, is a fundamental biological process that governs cellular responses to growth factors, adhesion cues, and immune stimuli. Its dysregulation is causally linked to cancer, developmental syndromes, and inflammatory diseases, as evidenced by mutations in LZTR1, KRAS, and CDC42 [1,2,4,7]. Understanding the molecular mechanisms, key genes, and regulatory networks involved is essential for developing targeted therapies. CRISPR-based models and advanced screening technologies now enable researchers to dissect these pathways with unprecedented precision. EDITGENE stands ready to support these efforts with custom cell model generation and bioinformatics services.
References
- 1. Soula M et al.. 2024. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer.. Nature 633(8029):451-458 PMID: 39112706
- 2. Motta M et al.. 2019. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.. Hum Mol Genet 28(6):1007-1022 PMID: 30481304
- 3. Wang X et al.. 2025. Ginseng exosomal miRNA ameliorates rheumatoid arthritis by mediating KRAS-MAPK signaling.. Int Immunopharmacol 161:115046 PMID: 40517734
- 4. Petshow S et al.. 2025. Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization.. Sci Adv 11(13):eadp5782 PMID: 40138406
- 5. Hu L et al.. 2022. MiR-1224-5p modulates osteogenesis by coordinating osteoblast/osteoclast differentiation via the Rap1 signaling target ADCY2.. Exp Mol Med 54(7):961-972 PMID: 35831436
- 6. Lanier LL. 1998. NK cell receptors.. Annu Rev Immunol 16:359-93 PMID: 9597134
- 7. Treekitkarnmongkol W et al.. 2026. RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.. Nat Cell Biol 28(1):197-206 PMID: 41326795
- 8. Hirano J et al.. 2024. Enterovirus 3A protein disrupts endoplasmic reticulum homeostasis through interaction with GBF1.. J Virol 98(7):e0081324 PMID: 38904364
